
NEWS RELEASE

Provid Announces New National Cancer Institute Contract

North Brunswick, NJ, September 29, 2005

Provid Pharmaceuticals Inc. announces the award of a \$750,000 phase II SBIR contract by the National Cancer Institute. The NCI and Provid will collaborate on a number of oncology targets over the next two years. Provid will apply its hypothesis-driven drug discovery chemistry to translate the assay hits into viable drug candidate leads for applications in cancer therapy. These projects emerged from the efforts of the Developmental Therapeutics Program Screening Technologies Branch at NCI, where small molecule assay hits have been identified and are ready for medicinal chemistry validation and optimization.

Dr. Gary Olson, Provid CEO, discussed the new contract. "We are excited about the expansion of Provid's role with the NCI to help discover drugs for cancer therapeutics, and with the opportunity to collaborate with the scientists who have uncovered the new research targets. The program is a great opportunity for Provid, and we value the confidence that the NCI has placed in us."

Provid Pharmaceuticals is a chemistry-based drug discovery company located in North Brunswick, New Jersey. The company works with biotech and pharmaceutical companies, academic groups, and research institutes to help develop small molecule drug leads for their targets. Provid also has a leading position in peptide mimetics technology and expertise in structure-based drug design, biochemical assays, and all aspects of medicinal chemistry. The company has also applied its technology in internal programs in autoimmune disease therapeutics, where it has candidates at preclinical stages for multiple sclerosis, rheumatoid arthritis, and celiac disease. More information is available at the company's web site, www.providpharma.com.

About Provid

Provid Pharmaceuticals Inc. is a drug discovery company that has expertise in the design and optimization of drug candidates for biological targets, using concepts of structure-aided design, medicinal chemistry, and peptide mimetics technology. The company has applied this capability to internal programs in autoimmune disease and oncology. In addition, Provid supplies expert medicinal chemistry services to the biotech and pharmaceutical industries to translate early biological discoveries into commercial opportunities.

Contacts:

Gary L. Olson, Ph.D.
President & CEO
Provid Pharmaceuticals Inc.
Princeton Corporate Plaza
9 Deer Park Drive
Monmouth Junction, NJ 08852
732-565-1101 x 626
732-565-3776 (FAX)
gary.olson@providpharma.com
www.providpharma.com